Effect of eplerenone on parathyroid hormone levels in patients with primary hyperparathyroidism: a randomized, double-blind, placebo-controlled trial

BMC Endocrine Disorders

Volumn 12, Issue , 2012, Pages

  Tomaschitz, Andreas ^a   Fahrleitner Pammer, Astrid ^a   Pieske, Burkert ^a   Verheyen, Nicolas ^a   Amrein, Karin ^a   Ritz, Eberhard ^b   Kienreich, Katharina ^a   Horina, Jörg H ^a   Schmidt, Albrecht ^a   Kraigher Krainer, Elisabeth ^a   Colantonio, Caterina ^a   Meinitzer, Andreas ^a   Pilz, Stefan ^a,c  

^a MEDICAL UNIVERSITY OF GRAZ   (Austria)

^b UNIVERSITY HOSPITAL HEIDELBERG   (Germany)

^c VU UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Aldosterone; Hyperparathyroidism; Mineralocorticoid receptor blocker

Indexed keywords

AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE; EPLERENONE; PARATHYROID HORMONE;

ADULT; ANTHROPOMETRY; ARTERIAL PRESSURE; ARTICLE; BLOOD PRESSURE MONITORING; BONE METABOLISM; CARDIOVASCULAR DISEASE; CLINICAL ASSESSMENT; CONTROLLED STUDY; DIASTOLIC BLOOD PRESSURE; DOUBLE BLIND PROCEDURE; DRUG DOSE TITRATION; DRUG EFFECT; ECHOCARDIOGRAPHY; FEMALE; HUMAN; KIDNEY FUNCTION; MAJOR CLINICAL STUDY; MALE; PARATHYROID HORMONE RELEASE; PRIMARY HYPERPARATHYROIDISM; RANDOMIZED CONTROLLED TRIAL; SYSTOLIC BLOOD PRESSURE;

EID: 84866131752     PISSN: None     EISSN: 14726823     Source Type: Journal    
DOI: 10.1186/1472-6823-12-19     Document Type: Article

References (49)

1. Wermers RA, Khosla S, Atkinson EJ, Achenbach SJ, Oberg AL, Grant CS, Melton LJ. Incidence of primary hyperparathyroidism in Rochester, Minnesota, 1993-2001: an update on the changing epidemiology of the disease. J Bone Miner Res 2006, 21(1):171-177.
2. Ogard CG, Sondergaard SB, Vestergaard H, Jakobsen H, Nielsen SL. Myocardial perfusion defects and the left ventricular ejection fraction disclosed by scintigraphy in patients with primary hyperparathyroidism. World J Surg 2005, 29(7):914-916. 10.1007/s00268-005-7740-1, 15951936.
3. Pilz S, Tomaschitz A, Drechsler C, Ritz E, Boehm BO, Grammer TB, März W. Parathyroid hormone level is associated with mortality and cardiovascular events in patients undergoing coronary angiography. Eur Heart J 2010, 31(13):1591-1598. 10.1093/eurheartj/ehq109, 20439261.
4. Hagstrom E, Hellman P, Larsson TE, Ingelsson E, Berglund L, Sundstrom J, Melhus H, Held C, Lind L, Michaelsson K, et al. Plasma parathyroid hormone and the risk of cardiovascular mortality in the community. Circulation 2009, 119(21):2765-2771. 10.1161/CIRCULATIONAHA.108.808733, 19451355.
5. Tomaschitz A, Pilz S, Ritz E, Meinitzer A, Boehm BO, März W. Plasma aldosterone levels are associated with increased cardiovascular mortality: the Ludwigshafen risk and cardiovascular health (LURIC) study. Eur Heart J 2010, 31(10):1237-1247. 10.1093/eurheartj/ehq019, 20200015.
6. Tomaschitz A, Pilz S, Ritz E, Grammer T, Drechsler C, Boehm BO, März W. Association of plasma aldosterone with cardiovascular mortality in patients with low estimated GFR: the Ludwigshafen Risk and Cardiovascular Health (LURIC) Study. Am J Kidney Dis 2011, 57(3):403-414. 10.1053/j.ajkd.2010.10.047, 21186074.
7. Fox CS, Gona P, Larson MG, Selhub J, Tofler G, Hwang SJ, Meigs JB, Levy D, Wang TJ, Jacques PF, et al. A multi-marker approach to predict incident CKD and microalbuminuria. J Am Soc Nephrol 2010, 21(12):2143-2149. 10.1681/ASN.2010010085, 3014027, 20966127.
8. Tomaschitz A, Pilz S, März W. Arterial hypertension and cardiovascular disease - absolute aldosterone excess is the tip of the iceberg. J Lab Med 2011, 35(3):147-152.
9. Pilz S, Tomaschitz A, März W, Cavalier E, Ritz E. Aldosterone and parathyroid hormone: a complex and clinically relevant relationship. Calcif Tissue Int 2010, 87(4):373-374. 10.1007/s00223-010-9409-5, 20721661.
10. Tomaschitz A, Ritz E, Pieske B, Fahrleitner-Pammer A, Kienreich K, Horina JH, Drechsler C, März W, Ofner M, Pieber TR, Pilz S. Aldosterone and parathyroid hormone - a precarious couple for cardiovascular disease. Cardiovasc Res 2012, 94(1):10-19. 1, 10.1093/cvr/cvs092, 22334595.
11. Mazzocchi G, Aragona F, Malendowicz LK, Nussdorfer GG. PTH and PTH-related peptide enhance steroid secretion from human adrenocortical cells. Am J Physiol Endocrinol Metab 2001, 280(2):E209-213.
12. Rosenberg J, Pines M, Hurwitz S. Response of adrenal cells to parathyroid hormone stimulation. J Endocrinol 1987, 112(3):431-437. 10.1677/joe.0.1120431, 3031192.
13. Chhokar VS, Sun Y, Bhattacharya SK, Ahokas RA, Myers LK, Xing Z, Smith RA, Gerling IC, Weber KT. Hyperparathyroidism and the calcium paradox of aldosteronism. Circulation 2005, 111(7):871-878. 10.1161/01.CIR.0000155621.10213.06, 15710759.
14. Eastell R, Arnold A, Brandi ML, Brown EM, D'Amour P, Hanley DA, Rao DS, Rubin MR, Goltzman D, Silverberg SJ, et al. Diagnosis of asymptomatic primary hyperparathyroidism: proceedings of the third international workshop. J Clin Endocrinol Metab 2009, 94(2):340-350. 10.1210/jc.2008-1758, 19193909.
15. Pilz S, Tomaschitz A, Stepan V, Obermayer-Pietsch B, Fahrleitner-Pammer A, Schweighofer N, Portugaller HR, Sourij H, Dobnig H, Meinitzer A, et al. Graz Endocrine Causes of Hypertension (GECOH) study: a diagnostic accuracy study of aldosterone to active renin ratio in screening for primary aldosteronism. BMC Endocr Disord 2009, 9:11. 10.1186/1472-6823-9-11, 2671510, 19351411.
16. Weinberger MH, Roniker B, Krause SL, Weiss RJ. Eplerenone, a selective aldosterone blocker, in mild-to-moderate hypertension. Am J Hypertens 2002, 15(8):709-716. 10.1016/S0895-7061(02)02957-6, 12160194.
17. Struthers A, Krum H, Williams GH. A comparison of the aldosterone-blocking agents eplerenone and spironolactone. Clin Cardiol 2008, 31(4):153-158. 10.1002/clc.20324, 18404673.
18. Sica DA. Pharmacokinetics and pharmacodynamics of mineralocorticoid blocking agents and their effects on potassium homeostasis. Heart Fail Rev 2005, 10(1):23-29. 10.1007/s10741-005-2345-1, 15947888.
19. Feldstein CA, Akopian M, Pietrobelli D, Olivieri A, Garrido D. Long-term effects of parathyroidectomy on hypertension prevalence and circadian blood pressure profile in primary hyperparathyroidism. Clin Exp Hypertens 2010, 32(3):154-158. 10.3109/10641960903254471, 20504122.
20. Pitt B, Remme W, Zannad F, Neaton J, Martinez F, Roniker B, Bittman R, Hurley S, Kleiman J, Gatlin M. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 2003, 348(14):1309-1321. 10.1056/NEJMoa030207, 12668699.
21. McMurray JJ, Adamopoulos S, Anker SD, Auricchio A, Bohm M, Dickstein K, Falk V, Filippatos G, Fonseca C, Gomez-Sanchez MA, et al. ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: the task force for the diagnosis and treatment of acute and chronic heart failure 2012 of the European society of cardiology. developed in collaboration with the heart failure association (HFA) of the ESC. Eur Heart J 2012, 33(14):1787-1847.
22. Bilezikian JP, Khan AA, Potts JT. Guidelines for the management of asymptomatic primary hyperparathyroidism: summary statement from the third international workshop. J Clin Endocrinol Metab 2009, 94(2):335-339. 10.1210/jc.2008-1763, 3214274, 19193908.
23. Amrein K, Amrein S, Drexler C, Dimai HP, Dobnig H, Pfeifer K, Tomaschitz A, Pieber TR, Fahrleitner-Pammer A. Sclerostin and its association with physical activity, age, gender, body composition, and bone mineral content in healthy adults. J Clin Endocrinol Metab 2012, 97(1):148-154. 10.1210/jc.2011-2152, 21994959.
24. Koal T, Schmiederer D, Tuan HP, Rohring C, Rauh M. Standardized LC-MS/MS based steroid hormone profile-analysis. J Steroid Biochem Mol Biol 2012, 129(3-5):129-138.
25. Pilz S, Kienreich K, Drechsler C, Ritz E, Fahrleitner-Pammer A, Gaksch M, Meinitzer A, März W, Pieber TR, Tomaschitz A. Hyperparathyroidism in patients with primary aldosteronism: cross-sectional and interventional data from the GECOH study. J Clin Endocrinol Metab 2012, 97(1):E75-79. 10.1210/jc.2011-2183, 22013107.
26. Silverberg SJ, Lewiecki EM, Mosekilde L, Peacock M, Rubin MR. Presentation of asymptomatic primary hyperparathyroidism: proceedings of the third international workshop. J Clin Endocrinol Metab 2009, 94(2):351-365. 10.1210/jc.2008-1760, 19193910.
27. Rodriguez-Ayala E, Avila-Diaz M, Foyo-Niembro E, Amato D, Ramirez-San-Juan E, Paniagua R. Effect of parathyroidectomy on cardiac fibrosis and apoptosis: possible role of aldosterone. Nephron Physiol 2006, 103(3):p112-118. 10.1159/000092244, 16557029.
28. Pacifici R, Perry HM, Shieber W, Biglieri E, Droke DM, Avioli LV. Adrenal responses to subtotal parathyroidectomy for primary hyperparathyroidism. Calcif Tissue Int 1987, 41(3):119-123. 10.1007/BF02563790, 3117338.
29. Kovacs L, Goth MI, Szabolcs I, Dohan O, Ferencz A, Szilagyi G. The effect of surgical treatment on secondary hyperaldosteronism and relative hyperinsulinemia in primary hyperparathyroidism. Eur J Endocrinol 1998, 138(5):543-547. 10.1530/eje.0.1380543, 9625366.
30. Brunaud L, Germain A, Zarnegar R, Rancier M, Alrasheedi S, Caillard C, Ayav A, Weryha G, Mirallie E, Bresler L. Serum aldosterone is correlated positively to parathyroid hormone (PTH) levels in patients with primary hyperparathyroidism. Surgery 2009, 146(6):1035-1041. 10.1016/j.surg.2009.09.041, 19958930.
31. Maniero C, Fassina A, Guzzardo V, Lenzini L, Amadori G, Pelizzo MR, Gomez-Sanchez C, Rossi GP. Primary hyperparathyroidism with concurrent primary aldosteronism. Hypertension 2012, 58(3):341-346.
32. Mihailidou AS, Le Loan TY, Mardini M, Funder JW. Glucocorticoids activate cardiac mineralocorticoid receptors during experimental myocardial infarction. Hypertension 2009, 54(6):1306-1312. 10.1161/HYPERTENSIONAHA.109.136242, 19841288.
33. Hulter HN, Melby JC, Peterson JC, Cooke CR. Chronic continuous PTH infusion results in hypertension in normal subjects. J Clin Hypertens 1986, 2(4):360-370.
34. Yoo YM, Baek MG, Jung EM, Yang H, Choi KC, Yu FH, Jeung EB. Parathyroid hormone-related protein and glucocorticoid receptor beta are regulated by cortisol in the kidney of male mice. Life Sci 2011, 89(17-18):615-620.
35. Moseley JM, Hayman JA, Danks JA, Alcorn D, Grill V, Southby J, Horton MA. Immunohistochemical detection of parathyroid hormone-related protein in human fetal epithelia. J Clin Endocrinol Metab 1991, 73(3):478-484. 10.1210/jcem-73-3-478, 1874927.
36. Olgaard K, Lewin E, Bro S, Daugaard H, Egfjord M, Pless V. Enhancement of the stimulatory effect of calcium on aldosterone secretion by parathyroid hormone. Miner Electrolyte Metab 1994, 20(5):309-314.
37. Letizia C, Ferrari P, Cotesta D, Caliumi C, Cianci R, Cerci S, Petramala L, Celi M, Minisola S, D'Erasmo E, et al. Ambulatory monitoring of blood pressure (AMBP) in patients with primary hyperparathyroidism. J Hum Hypertens 2005, 19(11):901-906. 10.1038/sj.jhh.1001907, 16034450.
38. Rubin MR, Maurer MS, McMahon DJ, Bilezikian JP, Silverberg SJ. Arterial stiffness in mild primary hyperparathyroidism. J Clin Endocrinol Metab 2005, 90(6):3326-3330. 10.1210/jc.2004-1400, 15769995.
39. Tomaschitz A, März W, Pilz S, Ritz E, Scharnagl H, Renner W, Boehm BO, Fahrleitner-Pammer A, Weihrauch G, Dobnig H. Aldosterone/renin ratio determines peripheral and central blood pressure values over a broad range. J Am Coll Cardiol 2010, 55(19):2171-2180. 10.1016/j.jacc.2010.01.032, 20447545.
40. Cooper JN, Tepper P, Barinas-Mitchell E, Woodard GA, Sutton-Tyrrell K. Serum aldosterone is associated with inflammation and aortic stiffness in normotensive overweight and obese young adults. Clin Exp Hypertens 2012, 34(1):63-70. 10.3109/10641963.2011.618200, 22007645.
41. Nilsson IL, Aberg J, Rastad J, Lind L. Endothelial vasodilatory dysfunction in primary hyperparathyroidism is reversed after parathyroidectomy. Surgery 1999, 126(6):1049-1055. 10.1067/msy.2099.101422, 10598187.
42. Morfis L, Smerdely P, Howes LG. Relationship between serum parathyroid hormone levels in the elderly and 24 h ambulatory blood pressures. J Hypertens 1997, 15(11):1271-1276. 10.1097/00004872-199715110-00011, 9383176.
43. Zia AA, Kamalov G, Newman KP, McGee JE, Bhattacharya SK, Ahokas RA, Sun Y, Gerling IC, Weber KT. From aldosteronism to oxidative stress: the role of excessive intracellular calcium accumulation. Hypertens Res 2010, 33(11):1091-1101. 10.1038/hr.2010.159, 20827279.
44. Edelmann F, Tomaschitz A, Wachter R, Gelbrich G, Knoke M, Dungen HD, Pilz S, Binder L, Stahrenberg R, Schmidt A, et al. Serum aldosterone and its relationship to left ventricular structure and geometry in patients with preserved left ventricular ejection fraction. Eur Heart J 2012, 33(2):203-212. 10.1093/eurheartj/ehr292, 21856682.
45. Lemann J, Piering WF, Lennon EJ. Studies of the acute effects of aldosterone and cortisol on the interrelationship between renal sodium, calcium and magnesium excretion in normal man. Nephron 1970, 7(2):117-130. 10.1159/000179814, 5438899.
46. Cappuccio FP, Markandu ND, MacGregor GA. Renal handling of calcium and phosphate during mineralocorticoid administration in normal subjects. Nephron 1988, 48(4):280-283. 10.1159/000184942, 3362272.
47. van Diepen S, Majumdar SR, Bakal JA, McAlister FA, Ezekowitz JA. Heart failure is a risk factor for orthopedic fracture: a population-based analysis of 16,294 patients. Circulation 2008, 118(19):1946-1952. 10.1161/CIRCULATIONAHA.108.784009, 18936331.
48. Law PH, Sun Y, Bhattacharya SK, Chhokar VS, Weber KT. Diuretics and bone loss in rats with aldosteronism. J Am Coll Cardiol 2005, 46(1):142-146. 10.1016/j.jacc.2005.03.055, 15992648.
49. Carbone LD, Cross JD, Raza SH, Bush AJ, Sepanski RJ, Dhawan S, Khan BQ, Gupta M, Ahmad K, Khouzam RN, et al. Fracture risk in men with congestive heart failure risk reduction with spironolactone. J Am Coll Cardiol 2008, 52(2):135-138. 10.1016/j.jacc.2008.03.039, 18598893.